Reduced antibody response to SARS-CoV-2 in COVID-19 patients with newly diagnosed diabetes: a retrospective observational study

BMC Endocrine Disorders

Research

Naoya Otsubo¹  Chisato Maki¹  Tatsuya Fukuda²  Michinori Kohara³  Fumihiko Yasui³  Masanori Murakami⁴  Tetsuya Yamada⁴  Sachiko Wakai⁵  Hiroko Beppu⁵  Tomohide Hanawa⁶  Chise Sugita⁶ 

[1]Department of Endocrinology and Metabolism, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, 2-44-1 Kabuki-Cho, Shinjyuku-Ku, 160-8488, Tokyo, Japan

[2]Department of Endocrinology and Metabolism, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, 2-44-1 Kabuki-Cho, Shinjyuku-Ku, 160-8488, Tokyo, Japan

[3]Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

[4]Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

[5]Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

[6]Department of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan

[7]Department of Pulmonary Medicine, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan

关键词: Diabetes;    Immune system;    COVID-19;    Antibodies;    SARS-CoV-2;   

DOI  :  10.1186/s12902-023-01263-z

 received in 2022-06-09, accepted in 2023-01-02,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has dramatically impacted global health, and patients with type 2 diabetes have been identified as a high-risk group for COVID-19 infection and the development of severe disease. In response, this study aimed to evaluate whether patients with type 2 diabetes infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could develop antibody responses in the same manner as patients without diabetes, and whether there is a difference in antibody response to SARS-CoV-2 between patients with diabetes diagnosed prior to hospitalization, and those with newly diagnosed diabetes.MethodsSARS-CoV-2-specific immunoglobulin G (IgG) levels were quantified using two iFlash 3000 Chemiluminescence Immunoassay analyzer kits (Shenzhen YHLO Biotech Co., Ltd.) to detect IgG antibodies specific for nucleocapsid protein (IgG-N), and specific for the S1 subunit of the spike protein (IgG-S1). In 124 hospitalized patients with COVID-19, 40 patients with type 2 diabetes were matched to 40 patients without diabetes using propensity score matching (PSM).ResultsThere was no difference in IgG-N and IgG-S1 levels between the patients with diabetes and those without. Of patients with diabetes, 31 patients had known diabetes and nine patients had newly diagnosed diabetes. The median levels of IgG-N at 7–13 days in patients with newly diagnosed diabetes were significantly lower than those in patients with known diabetes (IgG-N; 10.9 vs. 31.0 AU/mL, p = 0.031, IgG-S1; 7.5 vs. 24.4 AU/mL, p = 0.023).ConclusionsEven after adjusting for covariates using PSM, COVID-19 patients with type 2 diabetes had comparable antibody responses to patients without diabetes. Patients with newly diagnosed diabetes had lower IgG-N and IgG-S1 production in the second week of the disease compared with those with previously known diabetes.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 4

Fig. 4

Fig. 3

Fig. 1